News & Updates
Filter by Specialty:
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024
Adding anlotinib to gefitinib improves PFS in treatment-naïve Chinese patients with EGFRmut NSCLC
Adding anlotinib to gefitinib significantly improves progression-free survival (PFS) in treatment-naïve Chinese patients with EGFR-mutated (EGFRmut) advanced non-small-cell lung cancer (NSCLC), according to the results of the FL-ALTER phase III study.
Adding anlotinib to gefitinib improves PFS in treatment-naïve Chinese patients with EGFRmut NSCLC
20 Aug 2024
Transplant-ineligible myeloma: Daratumumab added to VCD deepens haematological response, improves PFS
Addition of daratumumab to the bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen provides deeper haematological responses and improves progression-free survival (PFS) in patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplantation (ASCT), according to the results of the AMaRC 03-16 phase II study.
Transplant-ineligible myeloma: Daratumumab added to VCD deepens haematological response, improves PFS
20 Aug 2024
Ongoing treatment required in severe patchy hair loss
For patients with severe alopecia areata who achieved meaningful hair regrowth with 1-year course of baricitinib, subsequent discontinuation appears to reverse treatment gains, highlighting the need for ongoing therapy.
